Pharmacotherapy of COVID-19: confine to existential drugs or search for new ones? (Preprint)

Author:

Hatip-Al-Khatib IzzettinORCID,Bolukbasi Hatip Funda

Abstract

UNSTRUCTURED

Background The recent COVID-19 outbreak (pandemic) has inflicted great human lives and economic losses. Aside from being abated, new surges in cases are being recorded. The sudden emergence and fulmination of the disease and its rapid spread caught the health authorities worldwide, including the developed ones, off guard, with no novel drugs available. Therefore there was no choice other than using the old drugs. Objectives This study aims to reveal the possible mechanism of action, adverse drug reactions and beneficial combination of drugs used in COVID-19 treatment Methods We undertook a comprehensive living structural review of COVID-19, searching databases, and other sources to identify literature on drugs used in the treatment of COVID-19. We analyzed the sources, publication date, type, and the topic of the retrieved articles/studies in the available search machines. Results Although a great number of literature on COVID-19 deals with pathology, clinic, and epidemiological issues, few studies that tackle pharmacology and toxicology of the drugs used could be found in the literature. At least twenty six (26) drugs, alone or in various combinations, are found in the literature to be used in various countries in the world. These drugs had been used previously for other purposes but they also possess activities that could target various steps involved in the virus invasion-replication-multiplication and leaving the cell. Pharmacokinetic fundamentals had also been applied in some combination (decrease Lopnavir’s metabolism by ritonavir), but some drugs that were initially extensively used at high doses without benefiting from some of their properties are recently being abandoned (hydroxychloroquine, ionophore for Zn2+). Conclusion The literature concerning drugs used in the treatment of COVID-19 lag far behind the great number of literature that discusses disease’s pathogenicity, clinical picture, and epidemiology. The World indeed had been caught unprepared for COVID-19, hence obliged to use old drugs.

Publisher

JMIR Publications Inc.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3